MCC might de-register Nevirapine

 This, after the Medicines Control Council (MCC) announced on Tuesday (29/07/03) that it rejects the findings of a re-monitoring report ordered in March last year into the conduct of the Uganda HIVNET-012 clinical study. It was this trial that formed the basis on which the drug was registered for the prevention of HIV from mother to child in South Africa, in 2001. Khopotso Bodibe reports.

To obtain the audio file please contact the Editor.

Author

Free to Share

Creative Commons License

Republish our articles for free, online or in print, under a Creative Commons license.


Stay in the loop

We love that you love visiting our site. Our content is free, but to continue reading, please register.

Newsletter Subscription

Be in the know with our free weekly newsletter. We deliver a round-up of our top stories and insightful reads from across the web.

  • This field is for validation purposes and should be left unchanged.

Enable Notifications OK No thanks